Cipla USA Inc.
www.ciplausa.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Cipla USA Inc.
Teva Pulls Out Its Digital Inhaler GoResp From UK Market
Commercial reasons led Teva to withdraw its innovative GoResp Digihaler from the UK market, asking healthcare professionals to stop supplying the inhaler immediately.
Rezafungin Review Highlights US FDA’s ‘Flexible Development' Approach For Antimicrobials
Cidara developed the antifungal for candidemia/invasive candidiasis pursuant to the FDA’s 2017 ‘Unmet Need guidance,’ which provides an avenue for approval with a 'limited use' indication based on a streamlined development program. Some of the guidance recommendations also have been leveraged under the LPAD pathway.
Who’s Hired? ANI Names New CEO
ANI Pharmaceuticals has chosen its new president and CEO to replace interim chief Patrick Walsh who stepped in after the departure Arthur Przybyl earlier this year. Meanwhile, key personnel announcements have also been made by Teva and Mylan.
Company Information
- Industry
-
Pharmaceuticals
- Generic Drugs
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice